SI20643B - IL-2-selektivni agonisti in antagonisti - Google Patents
IL-2-selektivni agonisti in antagonisti Download PDFInfo
- Publication number
- SI20643B SI20643B SI9920034A SI9920034A SI20643B SI 20643 B SI20643 B SI 20643B SI 9920034 A SI9920034 A SI 9920034A SI 9920034 A SI9920034 A SI 9920034A SI 20643 B SI20643 B SI 20643B
- Authority
- SI
- Slovenia
- Prior art keywords
- substituted
- mutein
- amino acid
- isoleucine
- valine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Predlozeni izum se nanasa na polipeptid, ki obsega humani IL-2-mutein, ostevilcen v skladu z IL-2 divjega tipa, pri cemer je humani IL-2 substituiranvsaj na enem od mest 20, 88 ali 126, pri cemer mutein prednostno aktivira celice T pred celicami NK. D20H in I, N88G, I in R imajo zlasti relativno T-celicno diferencialno aktivnost mnogo vecjo kot naravni IL-2 s predvideno zdruzeno zmanjsano toksicnostjo in vivo. Predlozeni izum vkljucuje tudi polinukleotide, ki kodirajo muteine v smislu izuma, vektorje, ki vsebujejo polinukleotide, transformirane gostiteljske celice, farmacevtske sestavke, ki obsegajo muteine in terapevtske postopke zdravljenja.
Claims (8)
1 Patentni zahtevki 1. Humani IL-2 mutein, oštevilčen ustrezno z IL-2 divjega tipa, ki ima aminokislinsko substitucijo pri enem od mest 20, 88 in 126, kjer: mesto 20 je substituirano z aminokislino, izbrano iz skupine, ki jo sestavljajo: alanin, histidin, izolevcin, metionin, glutamin, serin, valin ali tirozin; mesto 88 je substituirano z aminokislino, izbrano iz skupine, ki jo sestavljajo: alanin, arginin, glutaminska kislina, histidin, lizin, levcin, fenilalanin, glicin, izolevcin, metionin, serin, treonin, tirozin ali valin; mesto 126 je substituirano z aminokislino, izbrano iz skupine, ki jo sestavljajo: asparagin, levcin, prolin, fenilalanin, glicin, izolevcin, metionin, arginin, serin, treonin, tirozin ali valin; in pri čemer IL-2 mutein prednostno aktivira T-celice pred naravnimi celicami ubijalkami.
2. IL-2 mutein po zahtevku 1, kjer je mesto 88 substituirano z argininom.
3. Farmacevtski sestavek, ki obsega farmacevtski nosilec in humani IL-2 mutein po kateremkoli od zahtevkov 1 ali 2, pri čemer sestavek prednostno aktivira T-celice pred naravnimi celicami ubijalkami.
4. Humani IL-2 mutein, oštevilčen ustrezno IL-2 divjega tipa, ki ima substituciji pri dveh od mest 20, 88 in 126, kjer: mesto 20 je substituirano z aminokislino, izbrano iz skupine, ki jo sestavljajo: alanin, histidin, izolevcin, metionin, glutamin, serin, valin ali tirozin; 2 mesto 88 je substituirano z aminokislino, izbrano iz skupine, ki jo sestavljajo: alanin, arginin, glutaminska kislina, histidin, lizin, levcin, fenilalanin, glicin, izolevcin, metionin, serin, treonin, tirozin ali valin; mesto 126 je substituirano z aminokislino, izbrano iz skupine, ki jo sestavljajo: asparagin, levcin, prolin, fenilalanin, glicin, izolevcin, metionin, arginin, serin, treonin, tirozin ali valin; in pri čemer IL-2 mutein prednostno aktivira T-celice pred naravnimi celicami ubijalkami.
5. Polinukleotid, ki obsega DNA-sekvenco, ki kodira IL-2 mutein po kateremkoli od zahtevkov 1, 2 in 4.
6. Vektor, ki obsega polinukleotid po zahtevku 5.
7. Izolirana evkariontska celica, transformirana z vektoijem po zahtevku 6.
8. Prokariontska celica, transformirana z vektoijem po zahtevku 6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8008098A | 1998-05-15 | 1998-05-15 | |
| PCT/US1999/010643 WO1999060128A1 (en) | 1998-05-15 | 1999-05-13 | Il-2 selective agonists and antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20643A SI20643A (sl) | 2002-02-28 |
| SI20643B true SI20643B (sl) | 2008-02-29 |
Family
ID=22155135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9920034A SI20643B (sl) | 1998-05-15 | 1999-05-13 | IL-2-selektivni agonisti in antagonisti |
Country Status (39)
| Country | Link |
|---|---|
| EP (1) | EP1076704B1 (sl) |
| JP (1) | JP4276783B2 (sl) |
| KR (1) | KR100607609B1 (sl) |
| CN (2) | CN100366742C (sl) |
| AR (1) | AR020322A1 (sl) |
| AT (1) | ATE351907T1 (sl) |
| AU (1) | AU759697B2 (sl) |
| BG (1) | BG65139B1 (sl) |
| BR (1) | BRPI9910504B1 (sl) |
| CA (1) | CA2327349C (sl) |
| CO (1) | CO5070701A1 (sl) |
| CU (2) | CU23273B7 (sl) |
| CY (1) | CY1107533T1 (sl) |
| CZ (1) | CZ302071B6 (sl) |
| DE (1) | DE69934881T2 (sl) |
| DK (1) | DK1076704T3 (sl) |
| DZ (1) | DZ2788A1 (sl) |
| ES (1) | ES2281175T3 (sl) |
| HK (1) | HK1039963B (sl) |
| HN (1) | HN1999000075A (sl) |
| HU (1) | HU226142B1 (sl) |
| IL (2) | IL139136A0 (sl) |
| MY (1) | MY130274A (sl) |
| NO (1) | NO329235B1 (sl) |
| NZ (1) | NZ508098A (sl) |
| PA (1) | PA8472601A1 (sl) |
| PE (1) | PE20000475A1 (sl) |
| PL (1) | PL201675B1 (sl) |
| PT (1) | PT1076704E (sl) |
| RO (1) | RO122150B1 (sl) |
| RU (1) | RU2235729C2 (sl) |
| SI (1) | SI20643B (sl) |
| SK (1) | SK288100B6 (sl) |
| SV (1) | SV1999000061A (sl) |
| TN (1) | TNSN99090A1 (sl) |
| TR (1) | TR200003354T2 (sl) |
| TW (1) | TWI223663B (sl) |
| UA (1) | UA73719C2 (sl) |
| WO (1) | WO1999060128A1 (sl) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566500B1 (en) | 1999-03-30 | 2003-05-20 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
| EP1935431A3 (en) | 2000-05-15 | 2008-08-13 | Health Research, Inc. | Cancer treatments by using a combination of an antibody against her2 and interleukin-2 |
| US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| US7723102B2 (en) * | 2000-09-28 | 2010-05-25 | Bayer Corporation | Enhanced transfection system |
| MY139948A (en) * | 2000-09-28 | 2009-11-30 | Bayer Corp | Enhanced transfection system |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| MXPA04005266A (es) * | 2001-12-04 | 2004-10-11 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada. |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| DE602004031341D1 (de) | 2003-07-21 | 2011-03-24 | Transgene Sa | Multifunktionelle cytokine |
| WO2005014642A2 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
| PT1682178E (pt) | 2003-11-04 | 2010-10-21 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros que expressam o antigénio cd40 |
| EP1718670B1 (en) * | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| CN101244261B (zh) * | 2008-03-10 | 2010-09-15 | 山东大学 | 一种含未复性重组蛋白的生物制剂及其制备方法与应用 |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| CN102101885B (zh) * | 2010-09-01 | 2013-06-05 | 南京发士达生物科技有限公司 | 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途 |
| HUE054318T2 (hu) | 2010-11-12 | 2021-08-30 | Nektar Therapeutics | IL-2 molekularész konjugátumai és polimer |
| CU23923B1 (es) * | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| EP3075745B1 (en) | 2011-02-10 | 2018-09-05 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
| WO2012119093A1 (en) * | 2011-03-03 | 2012-09-07 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| EP3049445A4 (en) | 2013-09-24 | 2017-10-25 | Medicenna Therapeutics, Inc. | Interleukin-2 fusion proteins and uses thereof |
| PT3102595T (pt) | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| WO2016025385A1 (en) | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| US20200316118A1 (en) * | 2016-05-19 | 2020-10-08 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3475413B1 (en) * | 2016-06-22 | 2024-02-14 | David Klatzmann | Genetically modified t lymphocytes |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| CA3044416A1 (en) * | 2016-12-13 | 2018-06-21 | Delinia, Inc. | Multivalent regulatory t cell modulators |
| CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| EP3630162A1 (en) * | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
| EP3630813A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| CN111010866A (zh) | 2017-05-24 | 2020-04-14 | 潘迪恩治疗公司 | 靶向免疫耐受性 |
| EP3641814A4 (en) | 2017-06-19 | 2021-06-23 | Medicenna Therapeutics Inc. | USES AND METHODS FOR IL-2 SUPERAGONISTS, AGONISTS, AND FUSIONS THEREOF |
| AU2018309166B2 (en) * | 2017-08-03 | 2022-12-08 | Synthorx, Inc. | Cytokine conjugates for the treatment of proliferative and infectious diseases |
| KR20200086722A (ko) * | 2017-11-21 | 2020-07-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인터루킨-2의 부분 효능제 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| WO2019158764A1 (en) | 2018-02-16 | 2019-08-22 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
| EP3774861A1 (en) | 2018-03-28 | 2021-02-17 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
| KR20200139730A (ko) | 2018-03-28 | 2020-12-14 | 아센디스 파마 온콜로지 디비전 에이/에스 | Il-2 접합체 |
| WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
| WO2020020783A1 (en) * | 2018-07-24 | 2020-01-30 | Biontech Rna Pharmaceuticals Gmbh | Il2 agonists |
| EP3836954A1 (en) | 2018-08-13 | 2021-06-23 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| EP3715367B1 (en) * | 2018-09-17 | 2024-06-12 | GI Innovation, Inc. | Fusion protein comprising il-2 protein and cd80 protein, and use thereof |
| TW202034945A (zh) | 2018-12-21 | 2020-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素２變體或其衍生物 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| TW202115105A (zh) * | 2019-06-24 | 2021-04-16 | 德商拜恩迪克Ｒｎａ製藥有限公司 | Ｉｌ２激動劑 |
| JP2022544236A (ja) * | 2019-08-13 | 2022-10-17 | アムジエン・インコーポレーテツド | 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質 |
| JP2023505590A (ja) | 2019-12-12 | 2023-02-09 | イルトゥー・ファルマ | インターロイキン２キメラ構築物 |
| CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
| JP2023514010A (ja) | 2020-01-10 | 2023-04-05 | ブライト ピーク セラピューティクス エージー | 修飾ｉｌ－２ポリペプチドおよびその使用 |
| AU2021207652B2 (en) | 2020-01-14 | 2023-08-03 | Synthekine, Inc. | Biased IL2 muteins methods and compositions |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| EP4122952A4 (en) | 2020-03-19 | 2024-05-29 | Innovent Biologics (Singapore) Pte. Ltd. | INTERLEUKIN-2 MUTANT AND ITS USE |
| US11746137B2 (en) | 2020-03-31 | 2023-09-05 | Hanmi Pharm. Co., Ltd. | Immunostimulating IL-2 analogs |
| TW202210502A (zh) | 2020-06-03 | 2022-03-16 | 丹麥商阿森迪斯腫瘤製藥有限公司 | 新穎il-2序列及其用途 |
| WO2022094275A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| CN114507643A (zh) * | 2020-10-29 | 2022-05-17 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-2的多能干细胞衍生物及应用 |
| CN113308477A (zh) * | 2021-04-08 | 2021-08-27 | 华南农业大学 | 一种鸭il-2基因真核表达重组质粒及其制备方法 |
| IL311643A (en) | 2021-09-22 | 2024-05-01 | Fortvita Biologics Singapore Pte Ltd | Interleukin-2 mutant and fusion protein |
| WO2023057588A1 (en) | 2021-10-06 | 2023-04-13 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
| CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
| WO2023245097A2 (en) * | 2022-06-16 | 2023-12-21 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
| FR3140287A1 (fr) | 2022-10-03 | 2024-04-05 | Arkema France | Procede de granulation de composes azoiques et granules obtenus |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
-
1999
- 1999-05-12 DZ DZ990088A patent/DZ2788A1/xx active
- 1999-05-13 BR BRPI9910504A patent/BRPI9910504B1/pt not_active IP Right Cessation
- 1999-05-13 JP JP2000549735A patent/JP4276783B2/ja not_active Expired - Lifetime
- 1999-05-13 PL PL344407A patent/PL201675B1/pl unknown
- 1999-05-13 ES ES99924232T patent/ES2281175T3/es not_active Expired - Lifetime
- 1999-05-13 WO PCT/US1999/010643 patent/WO1999060128A1/en active IP Right Grant
- 1999-05-13 EP EP99924232A patent/EP1076704B1/en not_active Expired - Lifetime
- 1999-05-13 PE PE1999000399A patent/PE20000475A1/es not_active Application Discontinuation
- 1999-05-13 IL IL13913699A patent/IL139136A0/xx unknown
- 1999-05-13 HU HU0101948A patent/HU226142B1/hu unknown
- 1999-05-13 PA PA19998472601A patent/PA8472601A1/es unknown
- 1999-05-13 AT AT99924232T patent/ATE351907T1/de active
- 1999-05-13 TN TNTNSN99090A patent/TNSN99090A1/fr unknown
- 1999-05-13 PT PT99924232T patent/PT1076704E/pt unknown
- 1999-05-13 KR KR1020007012747A patent/KR100607609B1/ko not_active IP Right Cessation
- 1999-05-13 CN CNB998086509A patent/CN100366742C/zh not_active Expired - Lifetime
- 1999-05-13 SK SK1724-2000A patent/SK288100B6/sk not_active IP Right Cessation
- 1999-05-13 RU RU2000131593/04A patent/RU2235729C2/ru active
- 1999-05-13 DK DK99924232T patent/DK1076704T3/da active
- 1999-05-13 RO ROA200001123A patent/RO122150B1/ro unknown
- 1999-05-13 SI SI9920034A patent/SI20643B/sl active Search and Examination
- 1999-05-13 TR TR2000/03354T patent/TR200003354T2/xx unknown
- 1999-05-13 NZ NZ508098A patent/NZ508098A/en not_active IP Right Cessation
- 1999-05-13 UA UA2000127206A patent/UA73719C2/uk unknown
- 1999-05-13 DE DE69934881T patent/DE69934881T2/de not_active Expired - Lifetime
- 1999-05-13 CA CA2327349A patent/CA2327349C/en not_active Expired - Lifetime
- 1999-05-13 CN CN2007101609093A patent/CN101319247B/zh not_active Expired - Lifetime
- 1999-05-13 CZ CZ20004213A patent/CZ302071B6/cs not_active IP Right Cessation
- 1999-05-13 AU AU40784/99A patent/AU759697B2/en not_active Expired
- 1999-05-13 AR ARP990102269A patent/AR020322A1/es active IP Right Grant
- 1999-05-14 MY MYPI99001912A patent/MY130274A/en unknown
- 1999-05-14 HN HN1999000075A patent/HN1999000075A/es unknown
- 1999-05-14 TW TW088107812A patent/TWI223663B/zh not_active IP Right Cessation
- 1999-05-14 SV SV1999000061A patent/SV1999000061A/es active IP Right Grant
- 1999-05-14 CO CO99030158A patent/CO5070701A1/es unknown
-
2000
- 2000-10-18 IL IL139136A patent/IL139136A/en not_active IP Right Cessation
- 2000-11-08 BG BG104929A patent/BG65139B1/bg unknown
- 2000-11-14 NO NO20005762A patent/NO329235B1/no not_active IP Right Cessation
- 2000-11-15 CU CU20000257A patent/CU23273B7/es not_active IP Right Cessation
-
2002
- 2002-02-21 HK HK02101283.2A patent/HK1039963B/zh not_active IP Right Cessation
- 2002-06-19 CU CU20020125A patent/CU23272A1/es not_active IP Right Cessation
-
2007
- 2007-03-09 CY CY20071100330T patent/CY1107533T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI20643B (sl) | IL-2-selektivni agonisti in antagonisti | |
| ES2087207T3 (es) | Factor del crecimiento de fibroblasto quimerico. | |
| Bailey et al. | Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules | |
| DE69332908D1 (de) | Interleukin-3 (il-3)-polypeptide mith mehreren mutationen | |
| ATE491029T1 (de) | Fibroblasten-wachstumsfaktoren-homologe | |
| DE69630708D1 (de) | An den erythropoietin-rezeptor bindende zusammensetzungen und peptide | |
| ES2054365T3 (es) | Inhibicion de la via de la regla del n final en celulas vivas. | |
| KR970005043B1 (en) | Tumor necrosis factor alpha muteins | |
| NZ211386A (en) | Purification,cloning and characterisation of the gene for interlukin 1beta | |
| FI925972A (fi) | Ny polypeptid med affinitet till lipopolysackarider och dess anvaendning | |
| YAN et al. | Purification and the partial amino acid sequence of a novel activator of ryanodine receptor (BmK AS-1) from mammalian skeletal muscle | |
| DE3751398D1 (de) | Substrat-Peptide. | |
| AR009807A1 (es) | Peptidos que contienen analogos de cisteina. | |
| CA2455223A1 (en) | Crfr1 selective ligands | |
| AU6509098A (en) | Complement receptor type 1 (cr1)-like sequences | |
| RU96108242A (ru) | Полипептид, обладающий активностью устойчивой к холоду пируват-ортофосфатдикиназы, днк, кодирующая этот полипептид, рекомбинантный вектор и трансформированные растения, содержащие днк | |
| ATE432985T1 (de) | Polypeptide mit aktivität der stimulierung von neutrophilen | |
| NZ535467A (en) | Tick chitinase and methods for treating or preventign tick-borne infection | |
| KR950023650A (ko) | 인체 종양세포의 증식을 억제하는 인체 신경 아세포종 유래의 단백질 | |
| TH2482B (th) | สารคล้ายคลึง จี อาร์ เอฟ (grf) | |
| DK200200302A (da) | Rekombinante polypeptider omfattende aminosyresekvensen af moden vævsfaktorinhibitor (TFI), polypeptidfragmenter deraf, ekspressionsvektorer der koder for disse, værtsceller transformeret dermed, og fremgangsmåde til fremstilling af et ........ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| SP73 | Change of data on owner |
Owner name: AICURIS GMBH & CO. KG; DE Effective date: 20070511 |
|
| OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20071211 |